Literature DB >> 34711612

Gene-Level Germline Contributions to Clinical Risk of Recurrence Scores in Black and White Patients with Breast Cancer.

Achal Patel1, Montserrat García-Closas2,3, Andrew F Olshan1,4, Charles M Perou4,5,6, Melissa A Troester1,6, Michael I Love5,7, Arjun Bhattacharya8,9.   

Abstract

Continuous risk of recurrence scores (CRS) based on tumor gene expression are vital prognostic tools for breast cancer. Studies have shown that Black women (BW) have higher CRS than White women (WW). Although systemic injustices contribute substantially to breast cancer disparities, evidence of biological and germline contributions is emerging. In this study, we investigated germline genetic associations with CRS and CRS disparity using approaches modeled after transcriptome-wide association studies (TWAS). In the Carolina Breast Cancer Study, using race-specific predictive models of tumor expression from germline genetics, we performed race-stratified (N = 1,043 WW, 1,083 BW) linear regressions of three CRS (ROR-S: PAM50 subtype score; proliferation score; ROR-P: ROR-S plus proliferation score) on imputed tumor genetically regulated tumor expression (GReX). Bayesian multivariate regression and adaptive shrinkage tested GReX-prioritized genes for associations with tumor PAM50 expression and subtype to elucidate patterns of germline regulation underlying GReX-CRS associations. At FDR-adjusted P < 0.10, 7 and 1 GReX prioritized genes among WW and BW, respectively. Among WW, CRS were positively associated with MCM10, FAM64A, CCNB2, and MMP1 GReX and negatively associated with VAV3, PCSK6, and GNG11 GReX. Among BW, higher MMP1 GReX predicted lower proliferation score and ROR-P. GReX-prioritized gene and PAM50 tumor expression associations highlighted potential mechanisms for GReX-prioritized gene to CRS associations. Among patients with breast cancer, differential germline associations with CRS were found by race, underscoring the need for larger, diverse datasets in molecular studies of breast cancer. These findings also suggest possible germline trans-regulation of PAM50 tumor expression, with potential implications for CRS interpretation in clinical settings. SIGNIFICANCE: This study identifies race-specific genetic associations with breast cancer risk of recurrence scores and suggests mediation of these associations by PAM50 subtype and expression, with implications for clinical interpretation of these scores. ©2021 The Authors; Published by the American Association for Cancer Research.

Entities:  

Mesh:

Year:  2021        PMID: 34711612      PMCID: PMC8732329          DOI: 10.1158/0008-5472.CAN-21-1207

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  80 in total

1.  Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study.

Authors:  Lisa A Carey; Charles M Perou; Chad A Livasy; Lynn G Dressler; David Cowan; Kathleen Conway; Gamze Karaca; Melissa A Troester; Chiu Kit Tse; Sharon Edmiston; Sandra L Deming; Joseph Geradts; Maggie C U Cheang; Torsten O Nielsen; Patricia G Moorman; H Shelton Earp; Robert C Millikan
Journal:  JAMA       Date:  2006-06-07       Impact factor: 56.272

2.  RFMix: a discriminative modeling approach for rapid and robust local-ancestry inference.

Authors:  Brian K Maples; Simon Gravel; Eimear E Kenny; Carlos D Bustamante
Journal:  Am J Hum Genet       Date:  2013-08-01       Impact factor: 11.025

3.  A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer.

Authors:  Soonmyung Paik; Steven Shak; Gong Tang; Chungyeul Kim; Joffre Baker; Maureen Cronin; Frederick L Baehner; Michael G Walker; Drew Watson; Taesung Park; William Hiller; Edwin R Fisher; D Lawrence Wickerham; John Bryant; Norman Wolmark
Journal:  N Engl J Med       Date:  2004-12-10       Impact factor: 91.245

4.  Racial variation in breast tumor promoter methylation in the Carolina Breast Cancer Study.

Authors:  Kathleen Conway; Sharon N Edmiston; Chiu-Kit Tse; Christopher Bryant; Pei Fen Kuan; Brionna Y Hair; Eloise A Parrish; Ryan May; Theresa Swift-Scanlan
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2015-03-25       Impact factor: 4.254

5.  Supervised risk predictor of breast cancer based on intrinsic subtypes.

Authors:  Joel S Parker; Michael Mullins; Maggie C U Cheang; Samuel Leung; David Voduc; Tammi Vickery; Sherri Davies; Christiane Fauron; Xiaping He; Zhiyuan Hu; John F Quackenbush; Inge J Stijleman; Juan Palazzo; J S Marron; Andrew B Nobel; Elaine Mardis; Torsten O Nielsen; Matthew J Ellis; Charles M Perou; Philip S Bernard
Journal:  J Clin Oncol       Date:  2009-02-09       Impact factor: 44.544

6.  Matrix metalloproteinase expression and outcome in patients with breast cancer: analysis of a published database.

Authors:  P M McGowan; M J Duffy
Journal:  Ann Oncol       Date:  2008-05-23       Impact factor: 32.976

7.  Development and verification of the PAM50-based Prosigna breast cancer gene signature assay.

Authors:  Brett Wallden; James Storhoff; Torsten Nielsen; Naeem Dowidar; Carl Schaper; Sean Ferree; Shuzhen Liu; Samuel Leung; Gary Geiss; Jacqueline Snider; Tammi Vickery; Sherri R Davies; Elaine R Mardis; Michael Gnant; Ivana Sestak; Matthew J Ellis; Charles M Perou; Philip S Bernard; Joel S Parker
Journal:  BMC Med Genomics       Date:  2015-08-22       Impact factor: 3.063

8.  Race-associated biological differences among luminal A and basal-like breast cancers in the Carolina Breast Cancer Study.

Authors:  Humberto Parada; Xuezheng Sun; Jodie M Fleming; ClarLynda R Williams-DeVane; Erin L Kirk; Linnea T Olsson; Charles M Perou; Andrew F Olshan; Melissa A Troester
Journal:  Breast Cancer Res       Date:  2017-12-11       Impact factor: 6.466

9.  A gene-based association method for mapping traits using reference transcriptome data.

Authors:  Eric R Gamazon; Heather E Wheeler; Kaanan P Shah; Sahar V Mozaffari; Keston Aquino-Michaels; Robert J Carroll; Anne E Eyler; Joshua C Denny; Dan L Nicolae; Nancy J Cox; Hae Kyung Im
Journal:  Nat Genet       Date:  2015-08-10       Impact factor: 38.330

10.  Comparison of the Performance of 6 Prognostic Signatures for Estrogen Receptor-Positive Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial.

Authors:  Ivana Sestak; Richard Buus; Jack Cuzick; Peter Dubsky; Ralf Kronenwett; Carsten Denkert; Sean Ferree; Dennis Sgroi; Catherine Schnabel; Frederick L Baehner; Elizabeth Mallon; Mitch Dowsett
Journal:  JAMA Oncol       Date:  2018-04-01       Impact factor: 31.777

View more
  2 in total

1.  AKAP12 ameliorates liver injury via targeting PI3K/AKT/PCSK6 pathway.

Authors:  Xuan Wu; Yuhong Luo; Shan Wang; Yueying Li; Meiyu Bao; Yuanjiang Shang; Lei Chen; Weiwei Liu
Journal:  Redox Biol       Date:  2022-05-06       Impact factor: 10.787

2.  Integrative genomic and transcriptomic analyses illuminate the ontology of HER2-low breast carcinomas.

Authors:  Enrico Berrino; Laura Annaratone; Sara Erika Bellomo; Giulio Ferrero; Amedeo Gagliardi; Alberto Bragoni; Dora Grassini; Simonetta Guarrera; Caterina Parlato; Laura Casorzo; Mara Panero; Ivana Sarotto; Silvia Giordano; Matteo Cereda; Filippo Montemurro; Riccardo Ponzone; Nicola Crosetto; Alessio Naccarati; Anna Sapino; Caterina Marchiò
Journal:  Genome Med       Date:  2022-08-29       Impact factor: 15.266

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.